[Cardiotoxicity of trastuzumab: mechanisms of development, diagnosis, treatment]

The review discusses mechanisms of trastuzumab cardio- toxicity. There are presented risk factors of development of the left ventricular dysfunction in treatment of a drug, among which the most important are the simultaneous administration of anthracycline antibiotics and the presence of associated cardiovascular diseases. There are discussed the features of cardiac management of patients receiving trastuzumab therapy that focuses on early detection of abnormalities of left ven- tricular function from the normality as well as measures aim- ing at preventing the occurrence of cardiac dysfunction and its treatment.